"Turn challenges into opportunities for growth, using tough times as springboards for positive change."
Seth Bogner currently serves as Chairman and CEO of HeartPoint Global Inc., where he merges his exceptional leadership abilities with his long-time goal of creating a business that is both profitable and socially responsible.
At HeartPoint Global, he and his team provide global, breakthrough medical solutions for cutting-edge cardiac care that are affordable, safe, and minimally invasive.
Heartpoint Global is the Cardiovascular Research Foundation (CRF) TCT 2023 Shark Tank (Innovation) Competition winner. Mr. Bogner was also named to the International Business Times (IBT) Social Capital Top 100 List for 2022.
With more than three decades of experience in principal investing, structured finance, restructurings, and merchant banking across numerous industries, Seth Bogner is a visionary entrepreneur who has served as the CEO and president of many funded and/or financed entities.
To date, he has closed over 200 investments and merger and acquisition transactions during his career.
Check out more interviews with entrepreneurs here.
WOULD YOU LIKE TO GET FEATURED?
All interviews are 100% FREE OF CHARGE
Table of Contents
We are thrilled to have you join us today, welcome to ValiantCEO Magazine’s exclusive interview! Let’s start off with a little introduction. Tell our readers a bit about yourself and your company.
Seth Bogner: I am the Chairman and CEO of HeartPoint Global, where I combine my leadership skills with a passion for creating profitable yet socially responsible businesses. HeartPoint Global offers breakthrough medical solutions for cutting-edge cardiac care that are affordable, safe, and minimally invasive.
With over three decades of experience in various industries, including principal investing and structured finance, I lead a team dedicated to transforming cardiovascular healthcare worldwide.
As a pioneer of breakthrough medical solutions, HeartPoint Global (HPG) is paving the way for citizens worldwide to receive affordable, cutting-edge cardiac care.
In response to the 92 percent of the world’s population that has no access to cardiac surgery, HeartPoint Global is a leading medical device company is on a mission to provide innovative, minimally invasive, and accessible cardiac care on a global scale to ensure those who would otherwise suffer from or die of cardiovascular disease receive the care they need.
In the past year, what is the greatest business achievement you’d like to celebrate with your team? Please share the details of that success.
Seth Bogner: Our greatest achievement in the past year was winning the Cardiovascular Research Foundation (CRF) Shark Tank Innovation Competition with our novel multi-lumen stent system, INTELLISTENT®, designed for interventional adjustment of pulmonary blood flow in congenital heart disease.
What sets us apart is our innovative adjustability through our multi lumen technology within the main pulmonary artery (MPA) or its branches. Our distinct capability lies in the precise adjustment of pressure and flow within the MPA or its branches, allowing for customization to meet individual patient requirements or accommodate patient growth following the initial intervention.
Surpassing 170 competing technologies, this recognition from leading interventional cardiologists validates our work and technology, promising a bright future. In March, we won the silver award in the UCSF-Stanford Pediatric Device Consortium Competition 2024.
This prestigious competition, supported by the Bay Area and Silicon Valley’s leading children’s hospitals and the FDA, has a proven track record of assisting companies like ours to advance. In 2018, UCSF and Stanford University joined forces to establish the UCSF-Stanford Pediatric Device Consortium, integrating the renowned innovation methodology of Stanford Biodesign.
This collaboration combines the expertise of two leading institutions to foster the development of pediatric medical devices.
Stanford Biodesign’s proven model for device development has already resulted in the launch of 46 successful startup companies, impacting over a million patients worldwide. During the same month, HeartPoint Global was also named a winner of the Cardiovascular Research Technologies (CRT) 2024 top innovation award, further validating our advancements.
HPG has made remarkable strides over the past year, successfully reaching key milestones that pave the way for clinical market entry and commercial adoption.
With these achievements in place, the focus now shifts to securing strategic partners who share our vision and are eager to collaborate on our journey.
Notably, HeartPoint Global has overcome traditional time barriers typically associated with investments in medical device companies, positioning us as an attractive opportunity for potential partners.
Quiet quitting, The Great Resignation, are an ongoing trend causing many businesses to struggle to keep talent engaged and motivated. Most are leaving because of their boss or their company culture. 82% of people feel unheard, undervalued, and misunderstood in the workplace. In your experience, what keeps employees happy? And how are you adapting to the current shift we see?
Seth Bogner: We prioritize results-driven teamwork and foster a culture of creativity and innovation at HeartPoint Global.
Our diverse team is passionate about our mission to help children with cardiovascular disease, driving synergy and collaboration.
We believe in hiring exceptional talent who share our vision, empowering them to contribute meaningfully.
By nurturing a supportive environment where every voice is heard and valued, we ensure employee satisfaction and engagement.
Online business keeps on surging higher than ever, B2B, B2C, online shopping, virtual meetings, remote work, Zoom medical consultations, what are your expectations for the year to come and how are you capitalizing on the tidal wave?
Seth Bogner: At HeartPoint Global, we use technology to reduce inequality in healthcare. HeartPoint Global is capitalizing on the surge in online healthcare by developing an innovative NFC data and patient portal.
We have plans to integrate this with our INTELLISTENT® system, which enables seamless data sharing with patients and the global medical community.
Additionally, we’re launching a sophisticated SaaS platform for medical professionals, offering training and support worldwide.
In line with HeartPoint Global’s conscious capitalism mission, for every paid subscription, we will provide one to a medical professional in a developing nation, advancing our mission to provide greater access to healthcare globally.
Business is all about overcoming obstacles and creating opportunities for growth. What do you see as THE real challenge right now?
Seth Bogner: There are more than three million undiagnosed cases of congenital heart disease in the United States alone. There is a great disparity of care worldwide which I believe is the real challenge.
At HeartPoint Global, our mission is to democratize healthcare, particularly for pediatric patients.
We’re focused on innovative solutions to overcome socioeconomic barriers and ensure equitable access to life-saving treatments.
Years 2020-2023 threw a lot of curve balls into businesses on a global scale. Based on the experience gleaned in the past years, how can businesses thrive in 2024? What lessons have you learned and what advice would you share?
Seth Bogner: Innovation and adaptability are key to thriving in 2024 amidst geopolitical uncertainties, economic challenges, and public health risks. Embrace opportunities for growth and leverage crises as catalysts for positive change.
Entrepreneurship drives job creation and productivity, making it crucial for economic recovery. As a leader, it is important to prioritize mission-driven initiatives, foster creativity, and remain resilient in the face of adversity.
What does “success” in 2024 mean to you? It could be on a personal or business level, please share your vision.
Seth Bogner: Success in 2024 for HeartPoint Global involves continuing with our priority of securing FDA approval for our breakthrough device and advancing our first-in-human clinical trials.
Securing this designation would substantially streamline our regulatory pathway, particularly given that our initial focus is on pediatric use.
By concentrating our resources and efforts on our initial pediatric indications, we aim to expedite FDA market authorization compared to pursuing a broader range of indications from the outset.
Focusing on pediatric approvals serves as a strategic anchor, facilitating the potential approval process for additional indications in the future.
This approach positions us to navigate regulatory pathways more efficiently than if we were to prioritize adult indications initially.
HeartPoint Global is poised to initiate its first-in-human clinical trials, marking a significant milestone in the company’s journey.
Concurrently, we are actively engaged in securing strategic partnerships and enrolling patients for clinical trials both in the United States and abroad.
Ultimately, success means saving lives and improving outcomes for children with congenital heart disease and pulmonary hypertension worldwide.
Jed Morley, VIP Contributor to ValiantCEO and the host of this interview would like to thank Seth Bogner for taking the time to do this interview and share his knowledge and experience with our readers.
If you would like to get in touch with Seth Bogner or his company, you can do it through his – Linkedin Page
Disclaimer: The ValiantCEO Community welcomes voices from many spheres on our open platform. We publish pieces as written by outside contributors with a wide range of opinions, which don’t necessarily reflect our own. Community stories are not commissioned by our editorial team and must meet our guidelines prior to being published.
